BioNTech Results Presentation Deck slide image

BioNTech Results Presentation Deck

First Quarter 2020 Financial Results (unaudited) - Profit and Loss ● ● ● ● 9 Cash and cash equivalents of EUR 452m (USD 495m) as of March 31, 2020 Additional EUR 217m (USD 236m) due in 2Q 2020 from Pfizer and Fosun Pharma (equity investments and non-dilutive deal upfront payments, partially received already) Net cash used in operating activities and investments into property, plant and equipment on track with previous guidance of EUR 300m (USD 329m¹) for base business plan (prior to impact of Neon Therapeutics acquisition and BNT162 program) Majority of BioNTech development costs for BNT162 program in 2020 will be funded via Pfizer and Fosun Pharma cost sharing, equity investments and upfront payments. (in million) Revenues resulting from collaboration and license agreements Revenues from other sales transactions Total revenues Cost of sales Gross profit Research and development expenses Sales and marketing expenses General and administrative expenses Other operating income less expenses Finance income less expenses Income taxes Loss for the period 1 Rate German Central Bank as of March 31, 2020 Three months ended March 31, 2019 € 21.9 4.3 € 26.2 2020 € 21.2 6.5 € 27.7 (5.9) € 21.8 (65.1) (0.5) (15.8) 0.3 5.9 € (53.4) (3.3) € 22.9 (57.2) (0.5) (9.3) 0.3 3.0 € (40.8) BIONTECH
View entire presentation